Healthcare
Xvivo Perfusion AB (publ)(XVIPF)
Live Price
Offline$29.00
+0.00% today
Window Change
-1.32%
Window
May 29, 2026 โ Jun 12, 2026
- Market Cap
- $8.63B
- Revenue Growth
- -1.5%
- EPS Growth
- -85.4%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 11 bars ยท May 29, 2026 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xvivo Perfusion AB (publ) (XVIPF) is a Healthcare stock with a market cap of $8.63B and listed on OTC. The stock last traded around $29.00 and down 1.3% across the available one-year price window (May 29, 2026 โ Jun 12, 2026). Baseline metrics include revenue growth of -1.5%, EPS growth of -85.4%, a dividend yield of 0.0%. What stands out right now is revenue -1.5%, EPS -85.4%, free cash flow -100.0% with operating margin 11.8% and ROIC 3.3%. Valuation already assumes a fairly strong business story at P/E 116.9 and price/sales 10.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XVIPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.5% vs +7.6% peer median
Operating Margin
Below sector median
+11.8% vs +19.4% peer median
P/E
Above sector median
116.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 24, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.5% and EPS is at -85.4%, with operating margin around 11.8%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XVIPF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
XVIPF Max Drawdown
-1.32%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XVIPF and SPY.
Company Overview
Xvivo Perfusion AB (publ)
Other OTC
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
- Leadership
- Christoffer Rosenblad
- IPO Date
- Jul 21, 2014
- Employees
- 193
- Street Address
- MAessans gata 10
- Mailing
- Gothenburg, 412 51
- Region
- Gothenburg, SE
- Reporting Currency
- USD
- Investor Line
- 46 3 17 88 21 50
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 116.9
- EV/EBITDA
- 62.4
- Price/Sales
- 10.3
- Price/Book
- 4.0
Growth
- Revenue
- -1.5%
- EPS
- -85.4%
- Free Cash Flow
- -100.0%
Profitability
- Gross Margin
- 65.2%
- Operating Margin
- 11.8%
- Net Margin
- 8.9%
- ROE
- 3.5%
- ROIC
- 3.3%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 4.52
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.